Categories
Change Password!
Reset Password!
Delgocitinib cream is a beneficial topical treatment for people with mild to severe chronic hand eczema.
Twice daily application of Delgocitinib cream was shown to relieve pain, itch, and other symptoms and signs of chronic hand eczema in a double-blind, phase IIb dose-ranging randomized clinical trial. The Hand Eczema Symptom Diary (HESD) was utilized by researchers to measure the impact of Delgocitinib cream on pain, itch, and 9 other important patient-reported signs and symptoms.
Throughout the course of 16 weeks, 258 volunteers with chronic hand eczema were randomly assigned to receive Delgocitinib cream at doses of 1, 3, 8, or 20 mg/g or cream vehicle. Through the HESD, the subjects daily evaluated 11 chronic hand eczema signs and symptoms on an 11-point numeric rating scale (exploratory outcome). Delgocitinib cream at dose of 20 mg/g was linked with a persistent and early decline in itching and pain, as well as a significant decrease of ≥4 points from baseline to week sixteen in 48.4% and 63.6% of volunteers, respectively (17.9% and 5.9% in case of cream vehicle).
In comparison to the cream vehicle, all evaluated signs and symptoms of chronic hand eczema (20 mg/g) showed improvements. Subjects with persistent hand eczema experienced less itching, pain, and other symptoms after using Delgocitinib cream. The HESD may be a valuable evaluation tool for managing chronic hand eczema based on the data's correlation with clinician-reported results.
Contact Dermatitis
Treatment with Delgocitinib cream improves itch, pain and other signs and symptoms of chronic hand eczema: Results from the Hand Eczema Symptom Diary in a phase IIb randomized clinical trial
Andrea Bauer et al.
Comments (0)